Founded in 1981 by two pioneering scientists, Repligen is a leader today in Protein A ligand manufacturing, and is focused on becoming a trusted solutions provider for bioprocessing.


Repligen was founded in 1981 by two distinguished scientists who pioneered breakthrough advances in science and technology.

ARich.jpgAlexander Rich was co-Chair of the Repligen Board of Directors until 2014.  He was a Professor at the Massachusetts Institute of Technology since 1958.  Considered a founding father of the field of molecular biology, he received the National Medal of Science in 1995.  He passed away on April 27, 2015 at 90 years old.



Paul_Schimmel_May_2010.jpgPaul Schimmel is the Ernest and Jean Hahn Professor at The Skaggs Institute for Chemical Biology at The Scripps Research Institute. He formerly was the John D. and Catherine T. MacArthur Professor of Biochemistry and Biophysics in the Department of Biology at the Massachusetts Institute of Technology.  His principal scientific contributions include the discovery of “The Second Genetic Code" and expansion of the functional genome.




Since it’s founding in 1981, Repligen has been a leading expert in Protein A. Repligen scientists first cloned the gene for Protein A in 1982, and the Company introduced the world’s first recombinant form of the ligand in 1985. For many years of it’s history, Protein A was sold as a source of non-dilutive revenue to support a number of drug development programs that the Company was pursuing.

Following the acquisition of disposable chromatography technology from BioFlash in 2010, and its transformative acquisition of Novozymes Biopharma AB in 2011 (which included additional Protein A ligands and growth factor products), Repligen quickly doubled its bioprocessing product revenue.

The strategic decision was made in 2012 to divert Repligen’s dual business model to a singularly focused model, based on building its bioprocessing business and taking the opportunity to leverage the strength of the biologics market without being tied to the success or failure of any particular drug.

Executing on this strategy, Repligen in 2014 completed it’s acquisition of the assets of Refine Technology, through which it gained the XCell™ ATF System, thereby balancing its upstream and downstream product offerings. Based on its long history of innovation and industry knowledge, Repligen has become a highly regarded source of technologies and solutions that are setting new standards for modern bioproduction.

To provide customers with the broadest selection of pre-packed chromatography columns from bench-scale to production-scale, Repligen acquired Atoll GmBH of Weingarten, Germany in April 2016.  The acquisition combines Repligen's OPUS® Columns for GMP purification with Atoll's MediaScout®  Columns for process development and screening, solidifying Repligen as a leading supplier in this fast-growing segment.

Repligen milestones
Scroll To Top